On December 14, Peger Biopharmaceuticals announced on the Hong Kong Stock Exchange that on December 12, 2025, the company entered into a placement agreement with the joint placement agent. According to this, the company has agreed to place a total of 5,136,000 placement shares to no less than six undertakers at a price of HK$58.41 per share on a best-effort basis through the joint placement agent. The placement price is HK$58.41 per share. H shares are 10% off the closing price of HK$64.90 per share as reported on the Stock Exchange on the date of the placement agreement. Assuming that all of the placed shares are fully placed, the estimated total proceeds and net proceeds from the placement would be approximately HK$299,993,760 and approximately HK$295,699,826, respectively.

On December 14, Peger Biopharmaceuticals announced on the Hong Kong Stock Exchange that on December 12, 2025, the company entered into a placement agreement with the joint placement agent. According to this, the company has agreed to place a total of 5,136,000 placement shares to no less than six undertakers at a price of HK$58.41 per share on a best-effort basis through the joint placement agent. The placement price is HK$58.41 per share. H shares are 10% off the closing price of HK$64.90 per share as reported on the Stock Exchange on the date of the placement agreement. Assuming that all of the placed shares are fully placed, the estimated total proceeds and net proceeds from the placement would be approximately HK$299,993,760 and approximately HK$295,699,826, respectively.